IDEAYA Biosciences Introduces IDE101 as a First-In-Class Inhibitor Candidate for CDKN2A-Deficiency in Solid Tumors
Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhibitor IDE892CDKN2A-deficiency is a common tumor suppressor loss prevalent in ~10-15% of…